In the BioHarmony Drug Report Database
Dexmedetomidine, Precedex, Dexdor (dexmedetomidine) is a small molecule pharmaceutical. Dexmedetomidine was first approved as Dexmedetomidine on 1999-12-17. It is used to treat pain and psychomotor agitation in the USA. It has been approved in Europe to treat conscious sedation and premedication. It is known to target alpha-2B adrenergic receptor, alpha-2C adrenergic receptor, and alpha-2A adrenergic receptor. Precedex’s patents are valid until 2036-04-20 (FDA).
Image (chem structure or protein)